* Isis Pharmaceuticals Inc., of Carlsbad, Calif., signed an agreementwith Zeneca Ltd., of London, for the manufacture of Isis' anti-HIVcompound, ISIS 5320, a phosphorothioate oligonucleotide.

* Middlesex Sciences Inc., of Foxborough, Mass., raised $5.25million in venture financing, bringing the total financing since 1992to $10 million for the company that focuses on proprietary plasmafractionation.

* NeoRx Corp., of Seattle, and collaborating investigators presentedswine model data showing that the NeoRx drug Biosten inhibitedrestenosis.

* NeXagen Inc., of Boulder, Colo., and Colorado-based HauserChemical Research Inc. entered into an agreement for the contractmanufacture of NeXagen's oligonucleotide-based drug candidates.

* Ostex International Inc., of Seattle, signed an agreement withBoehringer Mannheim Diagnostics, of Gaithersburg, Md., tocollaborate to develop compatible applications of Ostex's bone-specific resorption assay and Boehringer Mannheim's diagnosticassay platforms.

* Sonus Pharmaceuticals, of Bothell, Wash., completed a Phase Itrial of its ultrasound contrast imaging agent, EchoGen Emulsion, in17 normal males.

* The Liposome Co. Inc., of Princeton, N.J., and investigatorsreported preclinical data showing a new drug, TLC C-53, mayimprove the treatment of heart attacks.

* Wellcome plc, of London, and Centocor Inc., of Malvern, Pa.,extended their alliance agreement entered into on Nov. 5, 1993, toextend Wellcome's rights to Centocor's monoclonal antibody-basedcancer product, Panorex, to include Japan, Taiwan, Korea and China.

(c) 1997 American Health Consultants. All rights reserved.